Venetoclax, CLAD/LDAC and azacitdine in older AML patients

Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AMLПодробнее

Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AML

Results from Venetoclax Added to CLAD Combo for Older Patients w/ #AML | Tapan Kadia, MD | ASH 2023Подробнее

Results from Venetoclax Added to CLAD Combo for Older Patients w/ #AML | Tapan Kadia, MD | ASH 2023

Venetoclax and azacitidine in older patients with AMLПодробнее

Venetoclax and azacitidine in older patients with AML

VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AMLПодробнее

VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AML

Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 yearsПодробнее

Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungalsПодробнее

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals

The role of venetoclax in older patients with AMLПодробнее

The role of venetoclax in older patients with AML

Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-mutated AMLПодробнее

Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-mutated AML

Pevonedistat, venetoclax and azacitidine for older AML patientsПодробнее

Pevonedistat, venetoclax and azacitidine for older AML patients

Venetoclax and azacitidine for AML ineligible for standard inductionПодробнее

Venetoclax and azacitidine for AML ineligible for standard induction

Venetoclax + azacitidine in unfit patients with AMLПодробнее

Venetoclax + azacitidine in unfit patients with AML

Venetoclax and azacitidine for young patients with AMLПодробнее

Venetoclax and azacitidine for young patients with AML

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”Подробнее

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”

Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AMLПодробнее

Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AML

allo-SCT improves survival following venetoclax and azacitidine therapy in AMLПодробнее

allo-SCT improves survival following venetoclax and azacitidine therapy in AML

Venetoclax plus azacitidine for higher-risk MDSПодробнее

Venetoclax plus azacitidine for higher-risk MDS

AML: Optimizing Selection and Use of Venetoclax + AzacitidineПодробнее

AML: Optimizing Selection and Use of Venetoclax + Azacitidine

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AMLПодробнее

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

Treating older patients with AML in 2020: What is new and promising?Подробнее

Treating older patients with AML in 2020: What is new and promising?

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AMLПодробнее

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AML